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ABSTRACT
Background. Immunoglobulin G4-related disease (IgG4-RD) is a fibro-inflammatory, immune-mediated disorder, which
characteristically affects the glandular tissue but has the potential to affect any organ.
Methods. We retrospectively reviewed clinical, laboratory, histological characteristics and treatment response during
12 months of follow-up of a cohort of patients with IgG4-RD diagnosed at a tertiary public hospital. Disease activity was
assessed by means of the IgG4-RD responder index (IgG4-RD RI).
Results. In all, 15 patients have been diagnosed at our Institution and herein studied (80% men), with a median age of
60.7 years and a mean affectation of 2.8 organs per patient. We identified six patients with definitive diagnosis and nine with
possible IgG4-RD, according to the Japanese diagnostic algorithm. IgG4-RD RI decreased from a median of 11.3 at baseline to
4.0 after 6 months and 6.2 after 12 months. Relapse occurred in five patients and was associated with lower cumulative
steroid doses. Five patients (33.3%) required additional immunosuppressive (IS) drugs. Five adverse events were seen during
follow-up: three infections, one deep vein thrombosis and one gastrointestinal bleeding. One patient died of pneumonia.
Conclusions. IgG4-RD is an inflammatory disease that can affect any organ. Glucocorticoids were an effective first line of
treatment; however, this treatment is associated with important adverse events and relapses occurred in patients with low
cumulative doses. As an alternative, IS treatment with rituximab could be an interesting option in those patients.
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INTRODUCTION
Immunoglobulin G4-related disease (IgG4-RD) is a fibro-inflam-
matory disorder usually characterized by affectation of glandu-
lar tissue, but with the potential to affect any other organ. The
disease was recognized as a systemic condition after 2003 when
extra-pancreatic manifestations were identified in patients
with autoimmune pancreatitis type 1 [1]. It was seen that
patients affected with autoimmune pancreatitis had fibro-
inflammatory lesions rich in IgG4 with similar findings in
organs other than pancreas, thus constellating the concept of
IgG4-related disease [2].
There are few population-based studies of this disease; how-
ever, some demographic data have been reported, such as male
predominance (62–83%) and its highest incidence during middle
age or elderly patients [3]. Clinically, this is an entity with vari-
able presenting symptoms and the potential to affect any organ
system, which makes it extremely difficult to diagnose. In gen-
eral, it may present as tumefacient lesions, manifested as pseu-
dotumoural injuries and atopic symptoms [3, 4]. Carruthers et
al. described a responder index of the disease (IgG4-RD RI), mod-
elled on the Birmingham Vasculitis Activity Score for Wegener’s
granulomatosis [5, 6]. Recently, Fernandez-Codina et al. [7] have
described that IgG4-RD RI could be a promising measure of the
activity of the disease and could be used to assess treatment
response.
Most serological findings are also non-specific. Many
patients with IgG4-RD have increased total serum IgG, IgG4 and
IgG1 concentrations, eosinophilia, hyperproteinaemia and com-
plement consumption, but none of these alterations was con-
sidered crucial for the diagnosis. Although IgG4 level are used in
diagnosis, it is of limited use for monitoring the disease during
follow-up [8].
Histology has been considered the gold standard for the di-
agnosis, with lymphoplasmacytic infiltrates composed of poly-
clonal CD20þ lymphocytes, T-cells and IgG4þ plasma cells in
immunohistochemistry (defined as 10 IgG4-bearing plasma
cells per high-power field or an IgG4/IgG plasma cell ratio
40%). Characteristically, the infiltrate is organized with a stori-
form pattern, obliterative phlebitis and tissue eosinophilia. The
inflammatory lesion is the structural basis of the tumefacien
mass that may destroy the involved organ. Granulomas and
neutrophils are rarely detected [3].
Regarding treatment, glucocorticoids (GCs) are considered
the first line of therapy. They are effective in most cases but re-
lapse rates at the time of dose reduction or after withdrawal of
treatment are high [9, 10]. Other immunosuppressive (IS) treat-
ments, such as mycophenolate mofetil (MMF), calcineurin
inhibitors (CNI) or rituximab (RTX), have been used to help pro-
long the period of remission or maintenance after remission
with GC therapy, but they are not useful to induce remission on
their own [4].
In the present article, we retrospectively reviewed all the
patients diagnosed with IgG4-RD at a tertiary university hospital
in Catalonia from 2008 to 2015.
MATERIALS AND METHODS
Study population
We retrospectively reviewed clinical, laboratory, histological
features and treatment response during 12 months of follow-up
of all patients diagnosed with IgG4-RD at our Institution, the
Hospital Universitari of Bellvitge (Barcelona, Catalonia, Spain)
from 2008 to 2015. The outcomes were evaluated at baseline,
and at 6 and 12 months.
We used the comprehensive diagnostic criteria for IgG4-RD
described by a Japanese group [11] stratifying patients into de-
finitive, probable and possible diagnostic of IgG4-RD (Table 1)
[12].
Clinical assessment
IgG4-RD RI score [6] was used to evaluate disease activity at the
moment of diagnosis, and 6 and 12 months later.
IgG4-RD RI score 3 was used to identify active disease, and
disease response was defined as a decrease of at least 2 points
over baseline, for six consecutive months [6]. Remission was de-
fined as IgG4-RD RI of 0, and relapses as recurrent symptoms,
an increased 2 in the IgG4-RD RI or the necessity for the restart
of treatment.
Complementary studies
A complete blood test was performed in all patients including
renal function, liver enzymes, haemogram, total immunological
study [immunoglobulins (Ig), IgG subtypes] and complement
fractions C3 and C4. Normal values in our laboratory are: IgG
from 6900 to 14 000 mg/L, IgG4 80–1400 mg/L, C3 750–1400 mg/L
and C4 100–340 mg/L.
Concerning histological analysis, we considered diagnostic
biopsy of IgG4-RD when previously described histological find-
ings were present (lymphoplasmocytic infiltrate composed of
polyclonal CD20þ lymphocytes, storiform pattern fibrosis, oblit-
erative phlebitis and tissue eosinophilia). Regarding immuno-
histochemical studies we considered compatible findings when
there were 10 IgG4-bearing plasma cells per high-power field
or an IgG4/IgG plasma cell ratio 40% [2].
In addition, a PET-SCAN or simple scan was performed in all
patients at diagnosis and, in some cases, during follow-up, with
the objective of monitoring metabolic changes in affected
organs.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6. We
used Kolmogorov–Smirnov test to check normal distribution,
and normally distributed variables were compared using the
Student’s t-test. A P-value <0.05 was considered statistically
significant.
RESULTS
Patients and clinical assessment
We included 15 patients in our study, 4 patients with definitive
diagnosis and 11 with possible IgG4-RD, according to compre-
hensive diagnostic criteria for IgG4-RD [12] (Table 2). Median age
at the time of diagnosis was 60.7 6 14.8 years (ranging from 30 to
80 years); males were more frequently affected (80%); and mean
organ involved was 2.8 6 1.2 organs per patient. There were two
cases with only one organ affected, four patients with two
organs, three organs were involved in six cases and the remain-
ing three patients had four (two patients) and seven (one pa-
tient) affected organs, respectively. Mainly affected organs were
adenopathies (60% patients), kidneys (40%), salivary glands
(33.3%), pancreas (20%), vascular disease (20%) and lungs (20%).
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Laboratory outcome
The mean value of IgG4 was 6823.3 mg/L (SD 67730.14) at base-
line, and 1676.8 mg/L (SD 6968.8) and 3804.9 mg/L (SD 64520.3)
at 6 and 12 months follow-up, respectively (Figure 1). All 15
patients had increased levels of IgG4 at baseline and in 13 of
them (86.7%) IgG4 decreased after 6 months of treatment. In the
two remaining cases (13.3%), IgG4 levels increased. When we
analysed these cases, in one patient, GCs were withdrawn after
3 months and the other had an erratic medication intake. Total
serum IgG was also increased in nine patients with a mean
value of 20 660.7 (SD 613 776.9), decreasing in seven patients
with a mean value of 11 214.6 (SD 64244.2) at 6 months of
treatment.
Regarding complement fractions (serum C3 and C4), we
obtained data from eight patients. Two of them had only one
reading during the follow-up. Six cases had complement frac-
tions at the time of diagnosis, and were clearly reduced in two
of them (33.3%), and in both cases the values corrected after 6
and 12 months of follow-up.
Four patients (26.7%) had hypereosinophilia, described as
>390 eosinophils/mL according to laboratory data of our hospi-
tal. Only one of the four patients persisted with high level of
eosinophils after 6 months, and also presented a relapse and
needed to add CNI to his treatment.
Considering renal function, six patients (40%) presented re-
nal failure (mean creatinine 274.15 mmol/L) and 33.3% presented
proteinuria [mean value 226.9 g/mol (SD 6317.3)]. Table 3 shows
renal function IgG4-RD RI and treatment progression, diagnostic
criteria, other affected organs and histological findings in this
cohort of patients.
Imaging studies
PET-SCAN was performed at the time of diagnosis in 11
patients; 6 of them (54.5%) evidenced hypermetabolism at
adenopathies, 4 (26.6%) at salivary glands, 4 (26.6%) at the gas-
trointestinal tract and 3 presented kidney hypermetabolism
(36.3%). Three patients presented pulmonary affectation, two of
them had vascular hypermetabolism and one patient had pros-
tatic affectation (6.7%). No patients had pancreatic hypermetab-
olism. This could be explained by physicians not performing the
exploration at the time of diagnosis in those patients.
During follow-up, four patients underwent a new PET-SCAN,
two at 6 months and the other two at 12 months; in all cases
there was a decrease in hypermetabolism, and in one patient, it
disappeared.
In Figure 2, we include a PET-SCAN study showing a focal
hypermetabolic lesion in the posterior wall of the bladder, and
an increased size left kidney with doubtful cortical uptake in re-
lation to acute renal failure versus underlying inflammatory
process. Doubtful morphometabolic asymmetry in left palatal
amygdala has been described, and increases in gastric level up-
take in a diffuse manner, probably physiological in the absence
of clinical symptoms (although not adequate gastric
preparation).
Histology
In our cohort, 10 patients had a diagnostic biopsy. In the other
five, histological confirmation was not done mainly because
their physicians made the diagnosis through reliable clinical
and imaging features, and an adequate and positive empirical
response to the treatment. More than that, the main affected
organs in those cases were the pancreas (50%) and an aortitis di-
agnosed through PET-SCAN (50%), which made access to biopsy
difficult.
The most frequent findings were: lymphoplasmocytic infil-
tration (80%) at different tissues, tissue eosinophilia (20%) and
in one sample (10%), storiform fibrosis. Immunohistochemical
studies of IgG4þ plasma cells were performed in eight biopsies
and were compatible with IgG4-RD diagnosis in 50% of cases. In
Figure 3 kidney biopsy is shown with lymphoplasmocytic infil-
tration with predominance of plasma cells in Figure 3A and an
immunohistochemical compatible study in Figure 3B.
Four patients had renal biopsy, which showed: tubulointer-
stitial nephritis (one patient), tubulointerstitial nephritis associ-
ated with minimal change disease (one patient), interstitial
fibrosis and glomerulosclerosis (one patient) and membranous
nephropathy associated with mild eosinophilic interstitial infil-
trate. In the last case, immunofluorescence showed a glomeru-
lar granular parietal pattern, positive for IgG, C3 and lambda
chains and IgG4-positive immunohistochemistry.
Table 1. Comprehensive clinical diagnostic criteria
Comprehensive clinical diagnostic criteria
(1) Clinical study shows characteristic diffuse/localized swelling or
masses in single or multiple organs
(2) Haematological study shows elevated levels of serum IgG4
(135 mg/dL)
(3) Histopathological study shows the following two findings
(i) Histological findings: marked lymphocyte and plasmacytic in-
filtration and fibrosis
(ii) IgG4-positive plasma cell infiltration: ratio of IgG4/IgG positive
cell >40%, and IgG4-positive plasma cells/HPF >10 of the
above
When (1), (2) and (3) are fulfilled, it is definite
When (1) and (3) are fulfilled, it is probable
When (1) and (2) are fulfilled, it is possible
However, it is important to differentiate from malignant tumours of
each organ (cancer, lymphoma, etc.) and similar diseases
(Sjogren’s syndrome, primary sclerosing cholangitis, Castleman’s
disease, secondary retroperitoneal fibrosis, Wegener’s granuloma-
tosis, sarcoidosis, Churg–Strauss syndrome, etc.) with additional
histopathological examination as much as possible
Even in the case that patients cannot be diagnosed with CCD criteria
for IgG4-RD, they may be diagnosed using organ-specific diagnos-
tic criteria for IgG4-RD
HPF, high-power field.
Table 2. Patients grouped according to the diagnostic criteria and





Four 1þ2þ3 Histological findings and IGG4-
positive plasma cell infiltration
Four 1þ2 Biopsy was not perform by
physician’s decission
One 1þ2 Biopsy was not perform by
patient’s decission
Five 1þ2 Histologically compatible but with
<40% of IGG4/IgG ratio and <10
IgG4-positive plasma cells/HPF
One 1þ2 Fibrosis and sclerosis
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One patient with kidney affectation presented a previous
perivesical biopsy that showed lymphoplasmacytic chronic in-
flammatory infiltration and lymphoid follicles. That patient had
already been diagnosed with IgG4-RD and was under treatment
with oral corticosteroids, and for this reason did not have a re-
nal biopsy.
Other biopsied organs were: submandibular gland (one pa-
tient), retroperitoneal tissue (two patients) with inflammatory
lymphoplasmocytic infiltration not conclusive for IgG4-RD and
chest wall with inflammatory lymphoplasmocytic infiltration
with immunihistochemical study compatible with IgG4-RD. One
patient had a lymphadenopathy biopsy suggestive of IgG4-RD.
Follow-up and treatment
All patients were followed up for 1 year. All of them received
oral prednisone at the diagnosis in a dosage of 0.5–1 mg/kg
depending on the severity of symptoms, and was tapered grad-
ually during follow-up.
All patients presented a clinical and analytical response in a
mean time of 5 6 2.6 months. IgG4-RD RI decreased from a me-
dian of 11.3 6 4.2 at baseline to 4.0 6 1.8 after 6 months and
6.2 6 5.5 to 12 months of therapy (Figure 4).
Five patients (33.3%) also needed IS therapy. One patient was
treated with CNI from diagnosis; he was initially misdiagnosed
with membranous nephropathy and initiated CNI before pred-
nisone, resulting in a temporary improvement of the protein-
uria with a subsequent relapse at 30 months. After the
beginning of the corticoid therapy, he presented an improve-
ment of the nephrotic syndrome and remained in remission for
2 years with low dosage of prednisone. Moreover, four patients
(26.7%) needed the addition of a second IS treatment, due to
clinical or analytical worsening in the context of low dose of
prednisone. In those cases, we used tacrolimus (1/5), MMF (4/5)
and RTX (1/5).
Relapses occurred in five patients. Prednisone dosage was
tapered gradually in patients with good response, and physi-
cians managed to withdraw it in three patients after 3, 9 and 15
months, respectively. These patients presented a relapse during
the first year of treatment (Figure 5) and needed to reintroduce





























































































































































































































































































































































































































































































































































































































































































































































































































































































FIGURE 1: IgG4 levels and IgG4 time.
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FIGURE 2: PET-SCAN. The picture shows a focal hypermetabolic lesion in the posterior wall of the bladder, and an increased left kidney size with doubtful cortical up-
take in relation to acute renal failure versus underlying inflammatory process. Doubtful morphometabolic asymmetry in left palatal amygdala has been described, and
increase in gastric level uptake in a diffuse manner, probably physiological in the absence of clinical symptoms (although not adequate gastric preparation).
FIGURE 3: Kidney biopsy. (A) Optical microscopy of kidney biopsy showing lymphoplasmocytic infiltration with predominance of plasma cells. (B)
Immunohistochemical study was performed objectifying >10 IgG4-bearing plasma cells per high-power field.
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a relapse under prednisone therapy, and 10 patients (66.7%)
showed no recurrence. Analysing patients who presented a re-
lapse, there was a tendency to less accumulated dose of cortico-
ids during the first year but it was not statistically significant. In
our cohort, patients who had a relapse had a median of 2.6 af-
fected organs (patients without relapse had 2.9 damaged
organs) and 66.7% of patients with pancreatic manifestation
presented a relapse.
Adverse events probably related to therapy occurred in five
patients (33.3%). From those, three patients presented an infec-
tion (three pneumonias and one of them a surgical wound in-
fection), one patient presented deep vein thrombosis and one a
low gastrointestinal bleeding during steroids treatment. Only
one patient died, because of respiratory failure due to pneumo-
nia 8 months after starting GC therapy.
DISCUSSION
In this article, we retrospectively analysed the main clinical,
histological features and evolution of all patients diagnosed
with IgG4-RD in our centre from 2008 to 2015. As some authors
described previously [3, 8, 13], considering demographic charac-
teristics, we found that IgG4-RD is a fibro-inflammatory condi-
tion with male predominance (80% in our population), affecting
people with a mean age of 60.7 years. Concerning clinical fea-
tures, in our analysis we found 86% of patients presented multi-
organ involvement, defined as disease affecting at least two
organs, a much higher percentage than Carruthers et al. [8] and
Campochiaro et al. [13], who found in their cohorts a 46.7% and
41.5% frequency of multi-organ involvement, respectively.
Regarding involved organs, mainly affected organs in our
patients were lymphadenopathies (53.3%), kidney affectation
(46.7%) and salivary glands (33.3%). In most cohorts [8, 13] pan-
creas is one of the most frequently affected organs (60% and
38.5%, respectively), and in contrast, in our cohort only 7.1% of
affected patients had a pancreatic condition.
When we compared laboratory findings we found similar val-
ues of serum IgG4 (6823.3 mg/L) as Carruthers et al. (6250 mg/L) [8].
In contrast, regarding complement factors, the same author
reported mean values of C3 and C4 within normality in all
patients (95 and 15 mg/dL, respectively) and we found only two
patients with low levels at diagnosis in our cohort. Although
IgG4-RD is often associated with allergic condition and hypereo-
sinophilia [3], we only found hypereosinophilia in 26.7% of
cases. Other series [13] found similar data describing hypereosi-
nophilia in 30.8% of patients.
We performed PET-SCAN at the diagnosis in 11 patients (73.3%)
and in the remaining four patients we performed a computed
tomography. Along same lines, Campochiaro et al. [13] described
that PET-SCAN was performed in 10 patients (38.5%) and the other
cases had SCAN or magnetic resonance imaging, depending on
organ involvement. In addition, in our population, we used PET-
SCAN also for evaluating treatment response in four patients and
we identified a decrease of the metabolism in all cases.
Concerning histological features, as described in other stud-
ies [13], not all biopsied patients diagnosed with IgG4-RD pre-
sented all histological criteria and in some cases the diagnosis
was considered ‘possible’ although not ‘definitive’ (in our cohort
six patients had definitive diagnosis fulfilling the three criteria:
clinical, haematological and histopathological). Campochiaro
et al. [13] did not find differences between those cases consid-
ered ‘definitive’ and the ‘possible’ ones, suggesting that all
patients presented the same disease.
Regarding treatment, all our patients were treated with GS
and we added other IS therapy in four patients. Currently, GCs
are the first line of therapy in these patients, by suppression of
lymphocyte activation and then reducing inflammation, includ-
ing vascular disease, as Mizushima et al. [14] described. In rela-
tion to alternative IS treatments, Carruthers et al. [8] described
in a prospective trial the efficacy of RTX in IgG4. RTX depletes
peripheral B cells provoking a decrease in plasmablast and
plasma cells that generate IgG4. They concluded that although
GCs remain the first treatment, in patients with contraindica-
tions to use them for long-term use, RTX could be an alternative
treatment. More recently, Quattrocchio et al. [15] studied the his-
tological effect of the treatment in a study that included five
patients (three with tubulointerstitial nephritis and two with
retroperitoneal fibrosis) with definite IgG4-RD who were treated
with RTX and GCs. They repeated renal biopsy after 12 months
of therapy in patients with tubulointerstitial nephritis, observ-
ing a remarkable reduction of interstitial plasma cell infiltrates,
and a normalization of IgG4/IgG positive plasma cells, and
FIGURE 4: IgG4-RD RI and IgG4 time.
FIGURE 5: Relapse in relation to GC dose received for a year.
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concluding that RTX might yield a more effective and long-
lasting response in IgG4-RD with kidney involvement.
In August 2017, a nationwide retrospective multicentre
study was performed to analyse safety and efficacy of RTX as
maintenance and induction therapy associated to other treat-
ments in patients with IgG4-RD [16]. These investigators identi-
fied that systematic RTX maintenance treatment was a
supposed protective factor, presenting a longer relapse-free sur-
vival. They did not find a different rate of relapse after compar-
ing patients with RTX and long-term maintenance of GCs
versus patients with RTX and withdrawal of GCs [16].
We found five patients presenting a relapse, three of them
related to GC discontinuation. In addition, in these patients we
found a tendency for a lower accumulated dose of corticoids
during the first year. There are few studies related to outcomes
of GCs therapy and in most of them the treatment was not dis-
continued, keeping low doses of them [9]. Hart et al. [17] de-
scribed in a multicentre report that relapse rates are higher in
those patients with intrahepatic biliary involvement and espe-
cially in patients with multi-organic affection, but we could not
find these differences in our study. Interestingly, this group also
described that relapse was most common in those patients with
GC therapy discontinuation, like our patients.
Regarding the side effects of the treatment, Campochiaro et al.
[13] did not find major adverse events related to GCs, highlighting
induced diabetes in 32.3% of studied patients. In contrast, we
reported five adverse events (33.3%) with one major adverse
event (one patient died due to pneumonia) in our cohort. It is im-
portant to remark that this disease affects more often the elderly
population who are more susceptible to severe adverse events.
In line with our findings and according to Perugino et al. [9],
we recommend initiating GCs at a dosage of 0.5–1 mg/kg
depending on the severity of symptoms, and keeping low doses
for at least the first year of treatment.
Our study has some limitations, the most important being
the short duration of follow-up, the retrospective nature of the
study and the fact that only 26.6% of cases have definitive diag-
nostics. It is important to remark that in 26.6% of cases patients
were not biopsied by physician’s decision, and the main af-
fected organs in those cases were pancreatic involvement (50%)
and aortitis diagnosed by PET-SCAN (50%).
In conclusion, in this manuscript we reported 15 patients
with IgG4-RD diagnosed in our centre. GCs were an effective
first line of treatment; however, they was related to substantial
adverse events, highlighting serious infections, and relapse
with lower cumulative doses or treatment discontinuation. In
light of, an alternative IS treatment, like RTX, could be an inter-
esting option for treating those patients.
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